Core Viewpoint - The company reported its 2025 performance, meeting market expectations with a revenue of 31.83 billion yuan, a year-on-year increase of 10%, and a net profit attributable to shareholders of 2.34 billion yuan, up 22% year-on-year [1] Revenue Growth - The company's overall revenue growth is driven by innovative products, with segment revenues as follows: oncology revenue reached 13.18 billion yuan (YoY +23%), liver/cardiovascular metabolism revenue at 6.69 billion yuan (YoY +19%), surgical/analgesia revenue at 5.03 billion yuan (YoY +13%), and respiratory/immunology revenue at 2.82 billion yuan (YoY -11%) [1] - Innovative product revenue for 2025 amounted to 15.22 billion yuan, representing a 26% year-on-year growth, increasing its revenue share to 47.8% [1] R&D Pipeline - The company continues to enhance its R&D pipeline, with ongoing clinical trials for various oncology treatments, including EGFR/c-Met bispecific antibodies entering Phase III for NSCLC and CCR8 monoclonal antibodies in registration trials for MSI-H/dMMR solid tumors and second-line gastric cancer [2] - In chronic disease management, the company is developing multiple weight-loss pipelines and next-generation siRNA therapies for cardiovascular diseases, with Lp(a) siRNA currently in Phase II clinical trials in China and the U.S. [2] Strategic Acquisitions - In July 2025, the company fully acquired Lixin Pharmaceutical to deepen its oncology portfolio, gaining access to leading antibody discovery and ADC technology platforms [2] - In January 2026, the company fully acquired Hejiya, obtaining the world's first clinically validated long-acting (annual injection) liver-targeted siRNA delivery platform, entering the chronic disease market [2] - The company plans to license global rights for Rovaxitinib, approved by NMPA in February 2026, to Sanofi, with an upfront payment of 135 million USD and potential total payments of up to 1.53 billion USD plus sales royalties, indicating a promising future revenue source from licensing [2] Profit Forecast and Valuation - The company has adjusted its net profit forecasts for 2026 and 2027 upwards by 3% and 2% respectively, estimating adjusted net profits of 5.06 billion yuan and 5.56 billion yuan [3] - The current stock price corresponds to adjusted P/E ratios of 19.5 and 17.5 for 2026 and 2027, maintaining an outperform rating with a target price of 8.90 HKD, suggesting a 51% upside potential from the current stock price [3]

Group 1 - The company, China Biologic Products Holdings, announced that on March 27, 2026, a trustee will purchase an additional 4.65 million shares from the market [1]

Group 1 - The company, China Biopharmaceutical (01177), announced the purchase of 4.65 million shares by a trustee from the market [1] - The average price per share for this transaction was approximately HKD 5.8814 [1] - The shares will be held in trust for selected participants according to the terms and conditions of the plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sbpgroup.com （股份編號：1177） 自願公告 根據限制性股份獎勵計劃購買股份 茲提述中國生物製藥有限公司（「本公司」）於二零一八年一月五日就本公司採納限制性股份獎勵計劃 （「該計劃」）作出的公告（「該公告」）。除文義另有所指外，本公告所用詞彙與該公告所界定者具有相同 涵義。 於二零二六年三月二十七日，受託人從市場進一步購買4,650,000股股份，並根據計劃規則的條款及 條件代獲選參與者以信託持有。受託人於二零二六年三月二十七日購買的股份詳情如下： 購買股份總數： 4,650,000股股份 購買股份佔目前已發行股份總數的百分比： 約0.025% 每股股份平均代價： 約5.8814港元 購買股份總代價： 約27,348,330港元 董事會將不時檢討及全權酌情決定將根據該計劃授予獲選參與者的股份數目及附帶董事會認為適合 的歸屬條件，以及繼續從市場 ...

Group 1 - The company, China Biopharmaceutical (01177), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 31.438 million [1] - The company plans to repurchase 5.35 million shares [1]

Group 1 - The core point of the article is that China Biologic Products Holdings (01177.HK) announced a share buyback plan, spending HKD 31.438 million to repurchase 5.35 million shares at a price range of HKD 5.85 to HKD 5.89 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國生物製藥有限公司 呈交日期： 2026年3月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01177 | 說明 - | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Core Viewpoint - Citigroup's report indicates that China Biologic Products (01177.HK) achieved a revenue increase of 10.3% year-on-year to 31.8 billion RMB, which is roughly in line with expectations, but the net profit rose by only 22% to 2.3 billion RMB, falling short of market and Citigroup's forecasts due to impairment of intangible assets and the termination of non-core businesses and joint ventures, laying the groundwork for future growth [1] Group 1 - Revenue for China Biologic Products increased by 10.3% year-on-year to 31.8 billion RMB, aligning with expectations [1] - Net profit rose by 22% year-on-year to 2.3 billion RMB, which was below market and Citigroup's expectations [1] - Management anticipates that 20 new products or new indications will be approved between 2026 and 2028, including M701 (CD3/EpCAM), TQB2101 (Her2/Her2 ADC), and LM302 (CLDN18.2 ADC) [1] Group 2 - Citigroup adjusted its revenue forecasts for 2026 and 2027, increasing the former by 3% and decreasing the latter by 1%, while lowering earnings per share forecasts by 16% and 18% due to expected increases in minority interests [1] - The target price for China Biologic Products was revised down from 10.8 HKD to 10 HKD, while maintaining a "Buy" rating [1] - Over the past 90 days, two investment banks have issued "Buy" ratings for the stock, with an average target price of 9.8 HKD [1] Group 3 - China Biologic Products has a market capitalization of 111.25 billion HKD, ranking second in the chemical pharmaceutical industry [1] - The latest report from CMB International Securities also gives a "Buy" rating for China Biologic Products, with a target price of 8.5 HKD [1]

Core Viewpoint - Citigroup's report indicates that China Biologic Products (01177) achieved a revenue increase of 10.3% year-on-year to 31.8 billion RMB, aligning closely with expectations, while net profit rose by 22% to 2.3 billion RMB, which fell short of market and Citigroup's forecasts due to impairment of intangible assets and the termination of non-core businesses and joint ventures, laying a foundation for future growth [1] Financial Performance - Revenue for the last year was 31.8 billion RMB, reflecting a year-on-year growth of 10.3% [1] - Net profit reached 2.3 billion RMB, representing a year-on-year increase of 22%, but was below market expectations [1] Future Growth Prospects - Management anticipates approval for 20 new products or indications between 2026 and 2028, including M701 (CD3/EpCAM), TQB2101 (Her2/Her2 ADC), and LM302 (CLDN18.2 ADC) [1] Analyst Adjustments - Revenue forecasts for 2026 and 2027 have been adjusted upwards by 3% and downwards by 1%, respectively [1] - Earnings per share forecasts have been reduced by 16% and 18% due to expected increases in minority interests [1] - Target price has been revised down from 10.8 HKD to 10 HKD, while maintaining a "Buy" rating [1]

Core Viewpoint - China National Pharmaceutical Group (Sino Biopharm) is following a unique growth path compared to other large domestic pharmaceutical companies, focusing on acquisitions and business development (BD) to enhance its innovation capabilities and global market presence [2][21]. Financial Performance - For the fiscal year 2025, Sino Biopharm reported revenue of 31.83 billion yuan, a year-on-year increase of 10.3%, and an adjusted net profit of 4.54 billion yuan, up 31.4% year-on-year [1]. - The revenue from innovative products reached 15.22 billion yuan, growing by 26.2% and accounting for 47.8% of total revenue, nearing the 50% mark [6]. - The gross profit margin improved to 82.1%, up 0.6 percentage points year-on-year, indicating a better profit structure despite price pressures from centralized procurement and medical insurance negotiations [8]. Strategic Acquisitions - In the past year, Sino Biopharm made significant acquisitions, including a full acquisition of Lixian Pharmaceuticals for $950 million, gaining access to a leading ADC technology platform and several potential first-in-class (FIC) assets [3]. - The company also acquired Hejiya for 1.2 billion yuan, obtaining the world's first clinically validated "once-a-year" long-acting siRNA delivery platform, targeting the multi-billion dollar chronic disease market [3]. - A global licensing collaboration with Sanofi for Rovaxitinib was established, valued at $1.53 billion, marking the highest record for outbound licensing in China's transplant field [3][12]. Business Development Strategy - Sino Biopharm employs a dual strategy of acquiring platforms and selling pipelines, which is rare among large domestic pharmaceutical companies [4]. - The company aims to make international revenue a visible part of its financial statements starting in 2026, with a focus on external licensing as a core performance metric [4][12]. Pipeline and Future Prospects - The company anticipates that nearly 20 first-class innovative drugs will be approved from 2026 to 2028, with a total of around 40 innovative products expected by the end of 2028 [13]. - Key products in the pipeline include Claudin 18.2 ADC and CCR8 monoclonal antibody, both of which have global FIC potential and are central to future business development efforts [15][16]. - The chronic disease segment is also accelerating, with products like Kylo-11 (Lp(a) siRNA) and plans for additional siRNA therapies [17][18]. Operational Efficiency - Sales and management expense ratio decreased from 42.1% to 41.3%, and productivity per employee doubled from 1.5 million yuan in 2019 to 3 million yuan [8]. - The company reported a net cash position of 16.9 billion yuan by the end of 2025, indicating a strong financial cushion for future acquisitions or licensing activities [8]. Corporate Identity and Focus - Sino Biopharm has officially changed its stock name to SBP Group, signaling a renewed focus on innovation and internationalization [20].